The stock has witnessed one downward estimate revision in the past 30 days. The Zacks Consensus Estimate also moved down over same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.
Aradigm Corporation carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
However, some better ranked stocks in the med-drugs industry include Endocyte, Inc. (ECYT), Hyperion Therapeutics, Inc. (HPTX) and Lannett Company, Inc. (LCI). All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment